Keros Therapeutics to Present at the Guggenheim SMID Cap Biotech Conference
(NasdaqGM:KROS), LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ss”) family of proteins, today announced that Keros' Chair […]